Clinical Trials Browser

Phase 1 × Recurrence × siltuximab × Clear all

NCT01309412 2014-05-19

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence